Since depletion of G2E3 decreases Chk1 activity, G2E3 inhibition may sensitize cancer cells in a similar way as Chk1 inhibition, a strategy which has been used in experimental cancer therapy as well as in early clinical studies [reviewed in 39, 40, 41]. Here, CHEK1 is linked to cancer.